Biosimilar Extrapolation

The fifth episode of the GHAPP & RhAPP Biosimilar Podcast Series takes a deep dive into one of the most crucial yet often misunderstood aspects of biosimilars—extrapolation. Hosted by Amanda Mixon, PA-C, this episode features Betsy Kirchner, DNP, a seasoned expert in rheumatology, as they break down the concept of biosimilar extrapolation and why it plays a pivotal role in the adoption of these therapies across multiple indications.Biosimilar extrapolation allows regulatory bodies like the FDA to approve biosimilars for multiple indications without requiring separate clinical trials for each condition. Instead, this approval is based on scientific justification, drawing from data on mechanism of action (MOA), pharmacokinetics (PK), immunogenicity, and overall biosimilarity to the reference product. By streamlining the approval process, extrapolation helps expand access to these treatments, making biologic therapies more affordable and widely available for patients in gastroenterology and rheumatology.During the discussion, Amanda and Betsy break down key aspects that support scientific justification for extrapolation, including how MOA remains consistent across different disease states, how PK and biodistribution studies confirm that the biosimilar behaves like its reference product, and how expected toxicities remain in line with the reference biologic. They also touch on real-world implications, such as insurance-driven biosimilar switches and how APPs can educate and reassure patients about biosimilar safety and efficacy.The conversation underscores the rigorous data-driven approach behind biosimilar extrapolation, reassuring clinicians and patients alike that these therapies undergo comprehensive analytical and clinical evaluations before approval. As biosimilars become a mainstay in the treatment of IBD, rheumatoid arthritis, and other chronic inflammatory diseases, understanding extrapolation is key for APPs, pharmacists, and physicians navigating biosimilar adoption in practice.Stay informed on the latest developments in biosimilars and rheumatology & GI care by subscribing to the GHAPP & RhAPPcast podcast series and accessing expert-driven resources on the RhAPP ACE App.Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-evall